<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:e89e2ae2-c766-4df3-b3fd-ba0f37e1af17,g:fb8da11f-c4bb-45fc-8030-a1b5c6730323,d:967c44464471446a81322ecddc66ada1--><html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>zsan-20211207</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV80L2ZyYWc6MGE3NzVjNzczZjkzNDQ1ZGE4ZTRhNDE4YTU0OTczYjEvdGFibGU6YjZmZjEzYWU5MGFkNDM0ZTlkOWNkMDcwNDIzZGQzNGUvdGFibGVyYW5nZTpiNmZmMTNhZTkwYWQ0MzRlOWQ5Y2QwNzA0MjNkZDM0ZV8wLTEtMS0xLTIyMTgw_cd819f83-6878-4ebb-9386-43df7d1d1eaa">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV80L2ZyYWc6MGE3NzVjNzczZjkzNDQ1ZGE4ZTRhNDE4YTU0OTczYjEvdGFibGU6YjZmZjEzYWU5MGFkNDM0ZTlkOWNkMDcwNDIzZGQzNGUvdGFibGVyYW5nZTpiNmZmMTNhZTkwYWQ0MzRlOWQ5Y2QwNzA0MjNkZDM0ZV8xLTEtMS0xLTIyMTgw_b815c333-2ef9-42ce-9ffc-aa666c2ae926">0001587221</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="zsan-20211207.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001587221</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-17</xbrli:startDate><xbrli:endDate>2021-11-17</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i967c44464471446a81322ecddc66ada1_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGV4dHJlZ2lvbjoxYTgxNjQzODM0NTY0ODE3YmNkYWNhODFiNDRkZmE1Zl8xMzM3_9a6dfbc3-2d10-4378-9c7a-ad16c8deb893">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGV4dHJlZ2lvbjoxYTgxNjQzODM0NTY0ODE3YmNkYWNhODFiNDRkZmE1Zl8yMjk_f829e1c3-8a45-4c39-aece-4e5b38370553">December 7, 2021</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGV4dHJlZ2lvbjoxYTgxNjQzODM0NTY0ODE3YmNkYWNhODFiNDRkZmE1Zl8xMzMy_0c64a463-37f9-4c32-8ac4-aa58720c604a">ZOSANO PHARMA CORPORATION</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:27.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGFibGU6NTYyYmMzMDk2NjY5NDA4Y2I5NDFjY2NjZDQxOGNiMWYvdGFibGVyYW5nZTo1NjJiYzMwOTY2Njk0MDhjYjk0MWNjY2NkNDE4Y2IxZl8wLTAtMS0xLTIyMTgw_d3aa3b35-3d4e-4f85-9fea-1671ee1bda05">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGFibGU6NTYyYmMzMDk2NjY5NDA4Y2I5NDFjY2NjZDQxOGNiMWYvdGFibGVyYW5nZTo1NjJiYzMwOTY2Njk0MDhjYjk0MWNjY2NkNDE4Y2IxZl8wLTItMS0xLTIyMTgw_59f0305d-fecb-4466-aecf-fb9b28500f04">001-36570</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGFibGU6NTYyYmMzMDk2NjY5NDA4Y2I5NDFjY2NjZDQxOGNiMWYvdGFibGVyYW5nZTo1NjJiYzMwOTY2Njk0MDhjYjk0MWNjY2NkNDE4Y2IxZl8wLTQtMS0xLTIyMTgw_bc4f7410-0fc7-4ea9-9647-5250a5dd31c6">45-4488360</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGV4dHJlZ2lvbjoxYTgxNjQzODM0NTY0ODE3YmNkYWNhODFiNDRkZmE1Zl8xMzMz_c66811a5-e9b7-4ce8-b6a3-a3dadf4643e6">34790 Ardentech Court</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGV4dHJlZ2lvbjoxYTgxNjQzODM0NTY0ODE3YmNkYWNhODFiNDRkZmE1Zl8xMzMw_25e55d7d-13cc-428d-887b-b8c286c03267">Fremont</ix:nonNumeric>, <ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGV4dHJlZ2lvbjoxYTgxNjQzODM0NTY0ODE3YmNkYWNhODFiNDRkZmE1Zl8xMzM4_c95d3f39-1dfe-463f-9da1-7c50cd568c14">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGV4dHJlZ2lvbjoxYTgxNjQzODM0NTY0ODE3YmNkYWNhODFiNDRkZmE1Zl8xMzMx_8f64e82d-742f-4379-9870-b5376c039441">94555</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGV4dHJlZ2lvbjoxYTgxNjQzODM0NTY0ODE3YmNkYWNhODFiNDRkZmE1Zl8xMzM0_0a00031e-dd99-4c0c-8a6b-2c0ce20c7e22">510</ix:nonNumeric>) <ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGV4dHJlZ2lvbjoxYTgxNjQzODM0NTY0ODE3YmNkYWNhODFiNDRkZmE1Zl8xMzM1_c5849d59-2a2f-43d9-89a6-a510036db6f7">745-1200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGFibGU6OWE2ODBhYTNmZTczNDliZWExYmYxN2RjNzFmM2UwMTAvdGFibGVyYW5nZTo5YTY4MGFhM2ZlNzM0OWJlYTFiZjE3ZGM3MWYzZTAxMF8wLTAtMS0xLTIyMTgw_5783887c-d219-4884-8194-7b2a652c55a1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGFibGU6OWE2ODBhYTNmZTczNDliZWExYmYxN2RjNzFmM2UwMTAvdGFibGVyYW5nZTo5YTY4MGFhM2ZlNzM0OWJlYTFiZjE3ZGM3MWYzZTAxMF8yLTAtMS0xLTIyMTgw_d9305a12-f5bb-43f3-b068-3f6660e4a197">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGFibGU6OWE2ODBhYTNmZTczNDliZWExYmYxN2RjNzFmM2UwMTAvdGFibGVyYW5nZTo5YTY4MGFhM2ZlNzM0OWJlYTFiZjE3ZGM3MWYzZTAxMF80LTAtMS0xLTIyMTgw_f9222b7f-f46a-4f0d-ad4b-5143aa866e5b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGFibGU6OWE2ODBhYTNmZTczNDliZWExYmYxN2RjNzFmM2UwMTAvdGFibGVyYW5nZTo5YTY4MGFhM2ZlNzM0OWJlYTFiZjE3ZGM3MWYzZTAxMF82LTAtMS0xLTIyMTgw_0c4adb10-1eab-4b50-b332-87ac7e058313">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:32.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGFibGU6MDgzODhhYTYxZGM0NDhkZjk4MTJhYThjY2YzZDVkZGUvdGFibGVyYW5nZTowODM4OGFhNjFkYzQ0OGRmOTgxMmFhOGNjZjNkNWRkZV8xLTAtMS0xLTIyMTgw_b03e257c-b7c1-4c39-bb2d-04d1b3ba4c20">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGFibGU6MDgzODhhYTYxZGM0NDhkZjk4MTJhYThjY2YzZDVkZGUvdGFibGVyYW5nZTowODM4OGFhNjFkYzQ0OGRmOTgxMmFhOGNjZjNkNWRkZV8xLTEtMS0xLTIyMTgw_92acdeae-9d64-4de8-9a89-1580919ee8f1">ZSAN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGFibGU6MDgzODhhYTYxZGM0NDhkZjk4MTJhYThjY2YzZDVkZGUvdGFibGVyYW5nZTowODM4OGFhNjFkYzQ0OGRmOTgxMmFhOGNjZjNkNWRkZV8xLTItMS0xLTIyMTgw_f20b051e-d521-43ef-ac78-82bea57f22a0">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160; <ix:nonNumeric contextRef="i16b7edb349fa42adbc4b19e1eb46c9f3_D20211117-20211117" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjk2N2M0NDQ2NDQ3MTQ0NmE4MTMyMmVjZGRjNjZhZGExL3NlYzo5NjdjNDQ0NjQ0NzE0NDZhODEzMjJlY2RkYzY2YWRhMV8xL2ZyYWc6MWE4MTY0MzgzNDU2NDgxN2JjZGFjYTgxYjQ0ZGZhNWYvdGV4dHJlZ2lvbjoxYTgxNjQzODM0NTY0ODE3YmNkYWNhODFiNDRkZmE1Zl8xMzM2_fc8c1f58-8bae-4ccd-afc2-fbdea376a7df">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;  &#9744;</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i967c44464471446a81322ecddc66ada1_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.02&#160;&#160;&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021, the Board of Directors (the &#8220;Board&#8221;) of Zosano Pharma Corporation (the &#8220;Company&#8221;) appointed Elaine Yang to serve as a member of the Board, effective immediately. Ms. Yang was appointed as a Class III director, to serve for an initial term expiring at the Company&#8217;s 2023 annual meeting of stockholders and until her successor is duly elected and qualified or until her earlier death, resignation or removal. Ms. Yang was also appointed to serve as a member of the Audit Committee of the Board.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company&#8217;s non-employee director compensation program, Ms. Yang will receive annual cash compensation of $45,000 for her service as a member of the Board and annual cash compensation of $7,500 for her service as a member of the Audit Committee of the Board. Also pursuant to the Company&#8217;s non-employee director compensation program, Ms. Yang was granted an option to purchase 90,000 shares of its common stock at an exercise price of $0.558 per share, which was the closing price of the Company&#8217;s common stock on the Nasdaq Capital Market on the date of grant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Yang and the Company will also enter into the Company&#8217;s standard form of indemnification agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 10, 2021, Kleanthis Xanthopoulos delivered notice of his intention to resign from the Board effective as of December 31, 2021. Dr. Xanthopoulos&#8217; resignation from the Board is not a result of a disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div><span><br/></span></div><div id="i967c44464471446a81322ecddc66ada1_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:41.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.843%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ZOSANO PHARMA CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: December 13, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christine Matthews</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Christine Matthews</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "zsan-20211207.htm", "description": "8-K", "secsgml_size_bytes": 35338}]
{"company-data": {"conformed-name": "Zosano Pharma Corp", "cik": "0001587221", "assigned-sic": "2834", "irs-number": "454488360", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36570", "film-number": "211488460"}, "business-address": {"street1": "34790 ARDENTECH COURT", "city": "FREMONT", "state": "CA", "zip": "94555", "phone": "510-745-1200"}, "mail-address": {"street1": "34790 ARDENTECH COURT", "city": "FREMONT", "state": "CA", "zip": "94555"}, "former-company": {"former-conformed-name": "ZP Holdings Inc", "date-changed": "20130919"}}
zsan-20211207
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
December 7, 2021
ZOSANO PHARMA CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
001-36570
45-4488360
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
34790 Ardentech Court
Fremont
,
CA
94555
(Address of principal executive offices) (Zip Code)
(
510
)
745-1200
Registrant's telephone number, including area code
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value
ZSAN
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐
Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 7, 2021, the Board of Directors (the "Board") of Zosano Pharma Corporation (the "Company") appointed Elaine Yang to serve as a member of the Board, effective immediately. Ms. Yang was appointed as a Class III director, to serve for an initial term expiring at the Company's 2023 annual meeting of stockholders and until her successor is duly elected and qualified or until her earlier death, resignation or removal. Ms. Yang was also appointed to serve as a member of the Audit Committee of the Board.
Pursuant to the Company's non-employee director compensation program, Ms. Yang will receive annual cash compensation of $45,000 for her service as a member of the Board and annual cash compensation of $7,500 for her service as a member of the Audit Committee of the Board. Also pursuant to the Company's non-employee director compensation program, Ms. Yang was granted an option to purchase 90,000 shares of its common stock at an exercise price of $0.558 per share, which was the closing price of the Company's common stock on the Nasdaq Capital Market on the date of grant.
Ms. Yang and the Company will also enter into the Company's standard form of indemnification agreement.
On December 10, 2021, Kleanthis Xanthopoulos delivered notice of his intention to resign from the Board effective as of December 31, 2021. Dr. Xanthopoulos' resignation from the Board is not a result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZOSANO PHARMA CORPORATION
Date: December 13, 2021
By:
/s/ Christine Matthews
Name: Christine Matthews
Title: Chief Financial Officer